ConductScience.org, home

Paper39476283

Antisense Oligonucleotides in Dyslipidemia Management: A Review of Clinical Trials.

Ogieuhi IJ and 11 others. High Blood Press Cardiovasc Prev, 2025. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Antisense Oligonucleotides in Dyslipidemia Management: A Review of Clinical Trials. Papers, record 39476283. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39476283

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Antisense Oligonucleotides in Dyslipidemia Management: A Review of Clinical Trials.
PubMed
Journal
High Blood Press Cardiovasc Prev
PubMed
Year
2025
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
3
iCite
Revised in PubMed
2026-11-01
PubMed

Authors12

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ogieuhi IJIkponmwosa Judehttps://orcid.org/0009-0003-9465-0089
2Callender KKristen
3Odukudu GOGod-Dowell O
4Obi ESEmeka Stanley
5Muzofa KKudzaishe
6Babalola AEAdetola Emmanuel
7Ugiomoh OMOshomoh Mark-Anthony
8Umenzeakor KHKenechukwu Hilary
9Akingbola AAdewunmi
10Ayoson COCharity Onetemizeh
11Agbo EUEmmanuel Uchenna
12Odoeke MCMoses Chukwuebuka

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
DyslipidemiasMajor topic
Oligonucleotides, AntisenseMajor topic
LipidsMajor topic
Hypolipidemic AgentsMajor topic
Humans
Treatment Outcome
Biomarkers
Apolipoprotein B-100
Clinical Trials as Topic

Source PubMed

Download CSV of topics

References59

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129361723Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs.Pharmacy (Basel)2018https://conductscience.org/library/papers/29361723PubMed
236614969Evinacumab, an ANGPTL3 Inhibitor, in the Treatment of Dyslipidemia.J Clin Med2022https://conductscience.org/library/papers/36614969PubMed
330500603Safety and efficacy of mipomersen in patients with heterozygous familial hypercholesterolemia.Atherosclerosis2019https://conductscience.org/library/papers/30500603PubMed
420378080Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy.J Am Coll Cardiol2010https://conductscience.org/library/papers/20378080PubMed
522247890The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases.J Adv Pharm Technol Res2011https://conductscience.org/library/papers/22247890PubMed
635902351Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia.J Clin Lipidol2022https://conductscience.org/library/papers/35902351PubMed
731103643Association Between Lipid Testing and Statin Adherence in the Veterans Affairs Health System.Am J Med2019https://conductscience.org/library/papers/31103643PubMed
823542898Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.Circ Res2013https://conductscience.org/library/papers/23542898PubMed
932178672Dyslipidemia and cardiovascular disease risk among the MASHAD study population.Lipids Health Dis2020https://conductscience.org/library/papers/32178672PubMed
1022388933Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping.Hum Mol Genet2012https://conductscience.org/library/papers/22388933PubMed
1132646313Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia.Expert Opin Pharmacother2020https://conductscience.org/library/papers/32646313PubMed
1231390500Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.N Engl J Med2019https://conductscience.org/library/papers/31390500PubMed
1325614280Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials.Arterioscler Thromb Vasc Biol2015https://conductscience.org/library/papers/25614280PubMed
1433123354Pelacarsen for lowering lipoprotein(a): implications for patients with chronic kidney disease.Clin Kidney J2020https://conductscience.org/library/papers/33123354PubMed
1512489851Antisense oligonucleotides: basic concepts and mechanisms.Mol Cancer Ther2002https://conductscience.org/library/papers/12489851PubMed
1621418033Antisense oligonucleotides for the treatment of dyslipidemia.Curr Pharm Des2011https://conductscience.org/library/papers/21418033PubMed
1723060426
Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
Circulation2012https://conductscience.org/library/papers/23060426PubMed
1824992960Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.Nucleic Acids Res2014https://conductscience.org/library/papers/24992960PubMed
1932604776Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development.J Clin Med2020https://conductscience.org/library/papers/32604776PubMed
2075545Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide.Proc Natl Acad Sci U S A1978https://conductscience.org/library/papers/75545PubMed

See all 59 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn PapersSource
42582720Gene Therapy for Lipid Management: Dawn of a New Era.Cureus2026https://conductscience.org/library/papers/42582720PubMed
41514470TMEM105 upregulation promotes colorectal cancer malignancy: a novel prognostic biomarker potentially linked to the MYC-Ribosome biogenesis axis.Cancer Cell Int2026https://conductscience.org/library/papers/41514470PubMed
41023586Genomic medicine in hepatology: mechanisms and liver treatment strategies.Mol Med2025https://conductscience.org/library/papers/41023586PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
APOB338PubTator's text mininghttps://conductscience.org/library/genes/338NCBI Gene
APOC3345PubTator's text mininghttps://conductscience.org/library/genes/345NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39476283

GET https://conductscience.org/api/papers/v1/39476283/references?page=2